Kennedy Ferruggia, Associate Editor

Treatment with LYT-200 is currently being assessed in a phase 1/2 adaptive design trial in advanced/metastatic solid tumors and in a phase 1b clinical trial.

The designation was granted based on overall survival data from an ongoing randomized phase 2 clinical trial.

Both dual primary endpoints—progression-free survival and overall survival—were met with durvalumab.

Aged mice displayed improvements in their spatial cognition, short-term memory, and muscle durability.

Study outcomes demonstrated that 80 HER2-postive BTC individuals enrolled in Cohort 1 of the study achieved a confirmed objective response rate of 41.3%

The positive results in both progression-free survival and overall response rate were endorsed in a confirmatory study.

Stephanie Ashraf, MD, offered clinical experience in managing insomnia at the American Medical Women’s Association (AMWA) 2024 Annual Meeting.

The recent ODD for the utidelone injectable could offer another treatment option for patients with BCBM.

The results displayed a dramatic reduction in the individuals’ tumors within days after single treatment.

Calder’s 3D Vaxlock technology attained 11 times more effective immune response, compared to typical comparator.

The adjuvanted RSVPreF3 vaccine could prevent nearly 3 million symptomatic RSV-ARI cases among US older adults over 3 years’ time, according to study results.

Benefits throughout post-progression endpoints and outcomes were reported for osimertinib in combination with chemotherapy.

All 20 participants in a 12-month follow-up study attained acute success from ablation procedures.

Pembrolizumab in combination with chemotherapy followed by maintenance olaparib did not meet its pre-specified statistical criteria of overall survival or progression free survival.

Zero relapses were reported among individuals that received ravulizumab-cwvz over the 73 weeks of treatment.

The test’s sensitivity in distinguishing colorectal cancer, in combination with real-world adherence, showed its ability to detect cancer at a curable stage.

The platform is a first-of-its-kind therapeutic approach to promote remyelination among individuals with relapsing/remitting multiple sclerosis.

The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.

Individuals included in the study reported positive changes in fatigue, and disease activity displayed endoscopic and histologic remission.

In the State of the Union Address, President Biden said he wants to expand the $2,000 out-of-pocket cap beyond seniors and allow Medicare to negotiate more costly drugs.

They also compared the approach of the European Medicines Agency and the FDA in drug approvals.

The at-home test offers the availability to assess for all viruses using one tool.

Study findings could provide scientists more knowledge on why some populations face a higher risk of lung cancer compared to others.

Only 9% of older adults who reside in the United States had been vaccinated to protect themselves from RSV this fall and winter.

Study findings suggest that biomarkers could provide greater insight into different disease mechanisms and how treatments options could be more beneficial for certain patients.

The finding highlighted the importance of RSV risks among older adults, and aids pharmacists’ awareness when patients are hesitant to receive the RSV vaccine.

The findings suggest that the CAR T-cell membrane-coated PLGA nanoparticles reduced tumor size after 1 dose of treatment.

If vorasidenib receives full approval, it would be a first-in-class target therapy to treat individuals with IDH-mutant gliomas.

Researchers from Gilead remain confident for positive results as they continue the phase 3 EVOKE-03 study in 1L metastatic PD-L1-high NSCLC.

The approval of irinotecan liposome offers an improved first-line treatment option for individuals diagnosed with metastatic pancreatic adenocarcinoma.